Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 12/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14433276 | 0.88 | CCR4 (1.00) | CCR4NPC1RAB9APOLBTDP1 | |
| SCHEMBL29274298 | 0.86 | CCR4 (0.76) | CCR4NPC1RAB9APOLBTDP1 | |
| SCHEMBL21708011 | 0.83 | CCR4 (0.71) | CCR4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL14433284 | 0.82 | CCR4 (1.00) | CCR4ALDH1A1GAAMAPT | |
| SCHEMBL14433280 | 0.80 | CCR4 (0.75) | CCR4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL5486145 | 0.79 | CCR4 (1.00) | CCR4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL14433279 | 0.76 | CCR4 (1.00) | CCR4ALDH1A1 | |
| SCHEMBL1135765 | 0.76 | CCR4 (0.61) | CCR4MAPK1ALDH1A1GAAMAPT | |
| SCHEMBL14433277 | 0.76 | CCR4 (0.69) | CCR4NPC1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL21708025 | 0.76 | CCR4 (0.76) | CCR4NPC1RAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | UNIVERSITY OF HEIDELBERG (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | UNIVERSITY OF HEIDELBERG (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3611256-A1 | APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE | Universität Heidelberg (DE) | 2020-02-19 | — | — | EP | disclosed |
| EP-3611256-A1 | APPLICATION OF IMIDAZOPYRIDINE DERIVATIVES IN REGENERATIVE MEDICINE | Universität Heidelberg (DE) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062719-A1 | Application of Imidazopyridine Derivatives in Regenerative Medicine | DOT1L, NSD1, KDM3A | CCR4 3403/4885NPC1 4209/4885RAB9A 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.